Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting of Shareholders
Business Wire - Fri Apr 18, 12:20PM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 24. To access the webcast, visit our website at www.pfizer.com/annualmeeting and click on the "Annual Meeting of Shareholders Webcast" link.
Most active New York Stock Exchange-traded stocks
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
Pfizer (PFE) Crosses Pivot Point Resistance at $30.23
Comtex SmarTrend(R) - Thu Apr 17, 12:31PM CDT
Shares of Pfizer (NYSE
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Early Glance: Pharmaceuticals companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Dow 30 Stock Roundup: JNJ Beats, JPM Disappoints - Analyst Blog
Swarup Gupta - Zacks Investment Research - Thu Apr 17, 9:46AM CDT
The Dow notched up substantial gains during a holiday shortened week, boosted by several positive factors.
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
Global Klebsiella Pneumoniae Infections Pipeline Review 2014 - Analysis of 12 Companies & 21 Drug Profiles
M2 - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frwd77/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Pfizer Inc. - Soligenix, Inc. - FOB Synthesis, Inc. - Phico Therapeutics Ltd. - Trana Discovery, Inc. - Cantab Biopharmaceuticals Limited - Procarta Biosystems Ltd - Northern Antibiotics Oy - Arsanis Biosciences GmbH Drug Profiles - CB-618 - RX-04 - Drugs for Gram-Negative Nonsocomial Infections - CB-027 - SM-295291 - SM-369926 - SGX-942 - Small Moleule To Inhibit Lipopolysaccharide For Nosocomial Infections - Antimicrobial Compounds for Bacterial Infections - NAB-741 - NAB-7061 - Monoclonal Antibody For Klebsiella Pneumoniae Infections - IBN-1 - PMBN-fMLF - PMEN-fMLF - FSI-1686 - SASPject PT-3.X - RX-05 - Snare Antibacterial For Gram Negative Infections - Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - MVX-506 For more information visit http://www.researchandmarkets.com/research/frwd77/klebsiella
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
Latin America OTC Pharmaceuticals Market 2014-2018 with Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
M2 - Wed Apr 16, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3ggp7m/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering. The OTC Pharmaceuticals Market in Latin America market to grow at a CAGR of 14% to 2018 One of the major drivers is the increasing switch from prescription to OTC drugs, which increases the number of OTC drugs available. The development and manufacture of drugs is a complex and time-consuming process, and it requires huge financial investments. As many vendors are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Certain vendors outsource different parts of the R&D process (such as product characterization testing and toxicology testing) to contract research organizations. Similarly, certain vendors are outsourcing part of their manufacturing process, or even the entire manufacturing process, to various organizations. Thus, outsourcing is one of the main trends in this market at present. Further, the report states that one of the major challenges in the market is the stringent regulations posed by regulatory bodies such as Ag?ncia Nacional de Vigil?ncia Sanit?ria, Brazil. Product recalls negatively affect a company's image, resulting in customers opting for other products available in the market, which leads to a fall in sales. Key vendors dominating this space include: - Bayer HealthCare AG. - EMS S.A. - Hypermarcas S.A. - Novartis AG. Other vendors mentioned in the report are: - Boehringer Ingelheim GmbH. - Genomma Lab Internacional SAB. - GlaxoSmithKline plc - Johnson & Johnson - Pfizer Inc - Takeda Pharmaceutical Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3ggp7m/otc
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...